[go: up one dir, main page]

AU7261881A - Therapeutically active compounds - Google Patents

Therapeutically active compounds

Info

Publication number
AU7261881A
AU7261881A AU72618/81A AU7261881A AU7261881A AU 7261881 A AU7261881 A AU 7261881A AU 72618/81 A AU72618/81 A AU 72618/81A AU 7261881 A AU7261881 A AU 7261881A AU 7261881 A AU7261881 A AU 7261881A
Authority
AU
Australia
Prior art keywords
sup
sub
group
groups containing
active compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU72618/81A
Other versions
AU539976B2 (en
Inventor
Otto Agne Torsten Olsson
Leif Ake Svensson
Kjell Ingvar Leopold Wetterlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Draco AB
Original Assignee
Draco AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Draco AB filed Critical Draco AB
Publication of AU7261881A publication Critical patent/AU7261881A/en
Application granted granted Critical
Publication of AU539976B2 publication Critical patent/AU539976B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/34—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton and at least one hydroxy group bound to another carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Luminescent Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

New bronchospasmolytically active compounds exhibiting long duration of action and reduced undesired side effects of the structural formulaand therapeutically acceptable salts thereof, in which formula R is selected from the group consisting of -C(CH<sub>3</sub>)<sub>3</sub>,andR<sup>1</sup> is selected from the group consisting of H and <sub>R2</sub>, R<sup>2</sup> represents the radical of the formulawherein R<sup>3</sup> is selected from the group consisting of(a) H(b) alkyl groups containing 1-3 carbon atomswherein R<sup>5</sup> is selected from the group consisting of(a) OH(b) alkoxy groups containing 1-3 carbon atoms and whereinR<sup>4</sup> is selected from the group consisting of(a) H(b) alkyl groups containing 1-3 carbon atoms, with the proviso that R<sup>3</sup> and R<sup>4</sup> are combined as follows:processes for the preparation thereof, chemical intermediates at their preparation, pharmaceutical preparations containing them, and their medicinal use.
AU72618/81A 1980-07-09 1981-07-07 Therapeutically active compounds Expired AU539976B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8022439 1980-07-09
GB8022439 1980-09-07
GB8116441 1981-05-29
GB8116441 1981-05-29

Publications (2)

Publication Number Publication Date
AU7261881A true AU7261881A (en) 1982-01-14
AU539976B2 AU539976B2 (en) 1984-10-25

Family

ID=26276161

Family Applications (1)

Application Number Title Priority Date Filing Date
AU72618/81A Expired AU539976B2 (en) 1980-07-09 1981-07-07 Therapeutically active compounds

Country Status (29)

Country Link
US (2) US4419364A (en)
EP (1) EP0043807B1 (en)
KR (3) KR850000301B1 (en)
AT (1) ATE7689T1 (en)
AU (1) AU539976B2 (en)
CA (1) CA1180021A (en)
CS (1) CS221845B2 (en)
CY (1) CY1273A (en)
DD (1) DD202001A5 (en)
DE (1) DE3163871D1 (en)
DK (1) DK157678C (en)
ES (3) ES503768A0 (en)
FI (1) FI73666C (en)
GR (1) GR74291B (en)
HK (1) HK5385A (en)
HU (2) HU184959B (en)
IE (1) IE51373B1 (en)
IS (1) IS1262B6 (en)
LU (1) LU88304I2 (en)
MX (1) MX9203239A (en)
MY (1) MY8700026A (en)
NO (2) NO152130C (en)
NZ (1) NZ197628A (en)
PH (2) PH16535A (en)
PL (1) PL128513B1 (en)
PT (1) PT73336B (en)
SG (1) SG79784G (en)
SU (1) SU1128830A3 (en)
YU (3) YU42116B (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904064D0 (en) * 1989-12-01 1989-12-01 Astra Ab IMPROVED METHOD OF PREPARING AND INTERMEDIATE FOR THE MANUFACTURE OF BAMBUTEROL
SE9000948D0 (en) 1990-03-16 1990-03-16 Draco Ab NEW USE
US5830422A (en) * 1995-06-23 1998-11-03 Ormiston Mining And Smelting Co. Ltd. Method for production of sodium bicarbonate, sodium carbonate and ammonium sulfate from sodium sulfate
AU2247997A (en) * 1996-01-29 1997-08-20 Savor, Evelyn P. Method of treating undesired uterine contractions using optically pure R-or RR-isomers of adrenergic beta-2 agonists
SE9604752D0 (en) * 1996-12-20 1996-12-20 Astra Ab Formulation and use
KR20030085658A (en) * 2002-04-30 2003-11-07 한올제약주식회사 An improved synthetic method of bambuterol
JP4979889B2 (en) * 2002-08-08 2012-07-18 タン，ダブリュー． Method for producing R-type bambuterol or a pharmaceutically acceptable salt thereof
US7495028B2 (en) * 2002-08-08 2009-02-24 Wen Tan R-bambuterol, its preparation and therapeutic uses
US7825147B2 (en) * 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
WO2006081986A1 (en) * 2005-02-07 2006-08-10 F.Hoffmann-La Roche Ag Bambuterol and integrin inhibitor combination
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
BRPI0617673C1 (en) * 2005-10-19 2012-05-22 Ranbaxy Lab Ltd phosphodiesterase type iv inhibitor compositions
WO2008023336A2 (en) 2006-08-22 2008-02-28 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
WO2008035315A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
DK2124944T3 (en) 2007-03-14 2012-04-23 Ranbaxy Lab Ltd Pyrazolo [3,4-b] pyridine derivatives as phosphodiesterase inhibitors
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
MX2013001240A (en) 2010-07-30 2013-08-27 Ranbaxy Lab Ltd METALOPROTEIN MATRIX INHIBITORS.
CN103228634A (en) 2010-09-24 2013-07-31 兰贝克赛实验室有限公司 Matrix metalloproteinase inhibitors
WO2014087298A1 (en) 2012-12-03 2014-06-12 Pfizer Inc. Novel selective androgen receptor modulators
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
CN104557614B (en) * 2014-12-15 2017-01-04 广东东阳光药业有限公司 A kind of method of reducing of amine
CN105622461B (en) * 2016-01-29 2018-06-19 华南理工大学 A kind of compound and its preparation method and application
CN105859589B (en) * 2016-04-05 2018-09-28 深圳市康立生生物科技有限公司 A method of preparing bambuterol impurity C
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CN109942462B (en) * 2019-03-06 2022-01-14 宏冠生物药业有限公司 Synthesis process of bambuterol hydrochloride
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
EP4651867A1 (en) 2023-01-20 2025-11-26 Atrogi AB Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting
GB202302225D0 (en) 2023-02-16 2023-04-05 Atrogi Ab New medical uses
GB202303229D0 (en) 2023-03-06 2023-04-19 Atrogi Ab New medical uses
CN117586152A (en) * 2023-11-23 2024-02-23 黑龙江乌苏里江制药有限公司 A kind of preparation method of bambuterol hydrochloride
GB202403169D0 (en) 2024-03-05 2024-04-17 Atrogi Ab New medical uses
WO2025238248A1 (en) 2024-05-17 2025-11-20 Atrogi Ab USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING
CN120585720A (en) * 2025-06-12 2025-09-05 肇庆学院 A nasal drug preparation for dual-target drugs and its application

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE178032C1 (en) 1961-01-01
DE1643488U (en) 1949-11-28 1952-09-11 G E Hilge Fa INCUBATOR.
DK85789C (en) 1955-07-05 1958-06-30 Cilag Ag Process for the preparation of d, 1- or 1-isopropyl-aminomethyl- (3,4-dihydroxy-phenyl) -carbinol or salts thereof.
DE1768167U (en) 1958-04-02 1958-06-04 Artur O Herrmann ROAD OBSTACLE WARNING DEVICE.
DE1275069B (en) 1960-02-15 1968-08-14 Boehringer Sohn Ingelheim 1- (3 ', 5'-dihydroxyphenyl) -1-hydroxy-2-isopropylaminoalkanes and processes for their preparation
NL123439C (en) 1961-09-14
FR1324857A (en) * 1962-06-14 1963-04-19 Chemie Linz Ag Process for the preparation of phenylethanolamine derivatives
GB1141606A (en) 1965-04-12 1969-01-29 Rech S Et D Applic Scient Et M Improvements in alkyl ethers of substituted phenylaminoethanols
DE1543372A1 (en) 1966-10-18 1971-04-01 Boehringer Sohn Ingelheim Process for the preparation of o-substituted 3,4-dioxyphenylalkanolamines
SE358633B (en) 1966-10-19 1973-08-06 Draco Ab
NO132866C (en) 1966-10-19 1976-01-21 Draco Ab
US3937838A (en) * 1966-10-19 1976-02-10 Aktiebolaget Draco Orally active bronchospasmolytic compounds and their preparation
SE335359B (en) 1966-10-19 1971-05-24 Draco Ab
FR6087M (en) 1967-01-10 1968-06-04
SE369299B (en) 1967-10-18 1974-08-19 Draco Ab
SE338324B (en) 1967-12-19 1971-09-06 Haessle Ab
GB1298771A (en) 1969-04-01 1972-12-06 Sterling Drug Inc Carboxylic esters of hydroxyphenylalkanolamines
AT294046B (en) 1969-07-08 1971-11-10 Chemie Linz Ag Process for the preparation of N, N'-bis [2- (3 ', 4'-dihydroxyphenyl) -2-hydroxyethyl] -hexamethylenediamine, its optically active forms and the salts thereof
US3657319A (en) * 1970-05-05 1972-04-18 Smith Kline French Lab Alpha-aminoalkyl-4-hydroxy-3-carboalkoxyaminobenzyl alcohols
NO126437B (en) 1970-08-05 1973-02-05 Draco Ab
NL7112938A (en) 1970-09-30 1972-04-05
CH550771A (en) 1970-10-30 1974-06-28 Hoffmann La Roche PROCESS FOR THE PRODUCTION OF PHENAETHYLAMINE DERIVATIVES.
US3876679A (en) 1970-12-09 1975-04-08 Aldrich Chem Co Inc Di-substituted phenethylcarbamic acid esters
NL7213759A (en) 1971-10-19 1973-04-25
US4011258A (en) 1973-06-21 1977-03-08 Aktiebolaget Draco Orally active bronchospasmolytic compounds
FI56673C (en) 1974-03-29 1981-02-04 Huhtamaeki Yhthymae Oy NYTT FOERFARANDE FOER FRAMSTAELLNING AV ALFA-TERT-BYTYLAMINOMETHYL-4-HYDROXY-M-XYLEN-ALFA1 ALFA3-DIOL
JPS556625B2 (en) * 1974-05-16 1980-02-18
US4063025A (en) * 1975-02-05 1977-12-13 Yamanouchi Pharmaceutical Co., Ltd. 4-Substituted amino-α-aminomethylbenzyl alcohol derivatives
SE7510988L (en) 1975-10-01 1977-04-02 Draco Ab NEW PHARMACEUTICAL ACTIVE ASSOCIATIONS
DE2710997C3 (en) * 1977-03-14 1980-08-14 Dr. Karl Thomae Gmbh, 7950 Biberach 4-Alkoxy carbonylamino-phenylethanolamines, their production and their use as pharmaceuticals

Also Published As

Publication number Publication date
FI73666C (en) 1987-11-09
EP0043807A2 (en) 1982-01-13
YU43169B (en) 1989-04-30
HU184959B (en) 1984-11-28
DE3163871D1 (en) 1984-07-05
DD202001A5 (en) 1983-08-24
IE811522L (en) 1982-01-09
GR74291B (en) 1984-06-21
NO812311L (en) 1982-01-11
ES513109A0 (en) 1983-03-01
NO152130C (en) 1985-08-07
DK157678B (en) 1990-02-05
PH16535A (en) 1983-11-10
ES8304534A1 (en) 1983-03-01
PH19447A (en) 1986-04-18
US4451663A (en) 1984-05-29
YU86383A (en) 1983-12-31
PL128513B1 (en) 1984-02-29
FI73666B (en) 1987-07-31
NZ197628A (en) 1985-07-12
IE51373B1 (en) 1986-12-10
PT73336B (en) 1983-09-01
KR830006174A (en) 1983-09-20
KR850002740A (en) 1985-05-15
AU539976B2 (en) 1984-10-25
SG79784G (en) 1985-04-26
PL232108A1 (en) 1982-08-02
MY8700026A (en) 1987-12-31
DK303481A (en) 1982-01-10
ES8304072A1 (en) 1983-02-16
KR850000870B1 (en) 1985-06-22
HU187611B (en) 1986-02-28
ES513108A0 (en) 1983-02-16
DK157678C (en) 1990-06-18
KR850000871B1 (en) 1985-06-22
MX9203239A (en) 1992-07-01
IS2657A7 (en) 1982-01-10
YU86483A (en) 1983-12-31
HK5385A (en) 1985-01-25
EP0043807A3 (en) 1982-09-22
NO152130B (en) 1985-04-29
FI812158L (en) 1982-01-10
NO1996008I1 (en) 1996-06-27
IS1262B6 (en) 1987-03-27
ATE7689T1 (en) 1984-06-15
CS221845B2 (en) 1983-04-29
CY1273A (en) 1985-03-08
CA1180021A (en) 1984-12-27
EP0043807B1 (en) 1984-05-30
LU88304I2 (en) 1994-05-04
YU43168B (en) 1989-04-30
KR850000301B1 (en) 1985-03-18
ES8300678A1 (en) 1982-11-01
YU170481A (en) 1983-12-31
PT73336A (en) 1981-08-01
KR850002741A (en) 1985-05-15
US4419364A (en) 1983-12-06
ES503768A0 (en) 1982-11-01
SU1128830A3 (en) 1984-12-07
YU42116B (en) 1988-04-30

Similar Documents

Publication Publication Date Title
AU539976B2 (en) Therapeutically active compounds
ES8404993A1 (en) Intermediates for the preparation of omeprazole.
SE8303013D0 (en) B-GAMMA DIHYDROPOLYPRENYLAL ALCOHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING A POLYPRENYL SUBSTANCE
DE3477488D1 (en) Polymethoxybenzyl piperazine derivatives, processes for their preparation and pharmaceutical compositions containing said derivatives
MY104540A (en) Pharmaceutical preparations.
JPS5271492A (en) Synthesis of 9-substituted-2-substituted thioadenines
JPS5283436A (en) Preparation of intermediates for synthesis of prostaglandin
JPS5219684A (en) Preparation of novel alpha-amino acid derivatives
JPS5227748A (en) Preparation of novel prostaglandin derivatives

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired